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a b s t r a c t
Humans encode seven APOBEC3 (A3A-A3H) cytidine deaminase proteins that differ in their expression
proﬁles, preferred nucleotide recognition sequence and capacity for restriction of RNA and DNA viruses.
We identiﬁed APOBEC3 hotspots in numerous herpesvirus genomes. To determine the impact of host
APOBEC3 on herpesvirus biology in vivo, we examined whether murine APOBEC3 (mA3) restricts murine
gammaherpesvirus 68 (MHV68). Viral replication was impaired by several human APOBEC3 proteins, but
not mA3, upon transfection of the viral genome. The restriction was abrogated upon mutation of the A3A
and A3B active sites. Interestingly, virus restriction by A3A, A3B, A3C, and A3DE was lost if the infectious
DNA was delivered by the virion. MHV68 pathogenesis, including lung replication and splenic latency,
was not altered in mice lacking mA3. We infer that mA3 does not restrict wild type MHV68 and
restriction by human A3s may be limited in the herpesvirus replication process.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Apolipoprotein B mRNA editing enzyme catalytic polypeptide-
like editing complex 3 (APOBEC3) proteins belong to a family of
host cytidine deaminases with a wide array of biological functions,
subcellular localization and tissue expression proﬁles (Bransteitter
et al., 2009; Smith et al., 2012). Eleven members of this enzyme
family have been discovered in humans; APOBEC1, APOBEC2,
APOBEC3, APOBEC4 and activation induced deaminase (AID).
APOBEC1 (A1), the founding member of this family, is an mRNA
editing enzyme that deaminates Apolipoprotein B mRNA to
produce two isoforms of apolipoproteins that are required for
low-density lipid formation(Driscoll and Zhang, 1994; Mehta and
Driscoll, 1998). APOBEC2 (A2) is a more recently discovered
member detected predominantly in the heart and skeletal muscle
(Mikl et al., 2005). Mice transgenic for human A2 develop lung and
liver tumors (Okuyama et al., 2012). APOBEC4 (A4) was discovered
by computational searches for genes homologous to A1 and, like
A2, has no ascribed function. The most widely studied members
are AID, which is critical for generating antibody diversity through
ssDNA deamination of the immunoglobulin locus, and APOBEC3
(A3) proteins, which act as innate immune barriers to the replica-
tion of viruses and endogenous retroelements (Cullen, 2006;
Refsland and Harris, 2013).
APOBEC3 genes have undergone duplication events in the
course of mammalian evolution. Murid rodents encode the single
APOBEC3, mA3, while felines encode four APOBEC3s (Munk et al.,
2008) and the equine genome encodes six (Bogerd et al., 2008).
Primates have an expanded repertoire of seven APOBEC3 proteins;
A3A, A3B, A3C, A3DE, A3F, A3G and A3H with each having slightly
different target sequences. A3s have been widely studied since the
identiﬁcation of human A3G (hA3G) as a host restriction factor of
viral infectivity factor (Vif)-deﬁcient HIV (Sheehy et al., 2002). In
Vif-deﬁcient HIV infections, hA3G is packaged into viral cores
through interactions with both the HIV nucleopcapsid protein and
the viral genomic RNA. A3G deaminates cytosine residues to
uracils in the newly synthesized strand. Vif enhances HIV replica-
tion by binding to hA3G and either targeting it for degradation or
preventing packaging into the HIV core (Goila-Gaur and Strebel,
2008; Zhang et al., 2003).
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Retroviruses, retroelements and more recently DNA viruses have
emerged as targets of hA3 proteins (Bishop et al., 2004; Delebecque
et al., 2006; Mahieux et al., 2005; Mangeat et al., 2003; Narvaiza
et al., 2009; Stenglein et al., 2010; Suspene et al., 2005a, 2005b, 2004;
Vartanian et al., 2008). Human A3A and A3C have been reported to
restrict herpes simplex virus type 1 (HSV-1) replication in transient
expression studies (Suspene et al., 2011). Additionally, Suspene et al.
(2011) reported the detection of virus variants consistent with
cytidine deamination in clinical specimens positive for either HSV-
1 or Epstein-Barr virus (EBV). However, in most cases the impact of
hA3 activity on the in vivo pathogenesis of a given virus in the host
has not been extensively studied. The murine APOBEC3 exhibits
antiviral activity against multiple murine and human retroviral
targets (Langlois et al., 2009; Low et al., 2009; Okeoma et al., 2007;
Takeda et al., 2008) implying that mA3 retains the retroviral
targeting function of the human A3. However, the antiviral function
of mA3 against herpesviruses is not known. In this report, we
examined the ability of mA3 to restrict murine gammaherpesvirus
68 (MHV68), a natural pathogen of murid rodents that has strong
genetic colinearity with, and biological similarities to, the human
gammaherpesviruses, Kaposi's sarcoma-associated herpesvirus
(KSHV/HHV-8) and Epstein Barr Virus (EBV). We determined the
distribution of A3 hotspots in the MHV68 genome, queried the effect
of A3 overexpression on viral replication and then ascertained the
impact of loss of A3 on in vivo pathogenesis. Although we observed
restriction of MHV68 replication with co-expression of several hA3s,
Fig. 1. APOBEC3 hotspots in herpesvirus genomes. (A) Percentage of 1 kb windows neutral, overrepresented or underrepresented for human and mouse APOBEC3 hotspots
in the indicated viral genome. (B) Heatmap of A3 hotspots in herpesvirus genomes. Scale indicates the percentage of 1 kb windows of the viral genome with
overrepresentation or underrepresentation of hotspots as described in (A). (C) Distribution of 1 kb regions of the MHV68 genome overrepresented (red bars) or
underrepresented (blue bars) for the indicated A3 hotspots. The boundary of each bar corresponds to the midpoint of the ﬁrst and last 1 kb window represented within the
bar. The gray trace represents the distribution of the hotspot occurrence in a region compared to the occurrence in 1000 randomly shufﬂed 1 kb genomic regions. The scale of
the trace is from 0.5 to 0.5, the numbers on the y-axis indicate the distance from the mean of each distribution (y¼0). Genomic regions are signiﬁcantly overrepresented
(red bars) or underrepresented (blue bars) if they are above 0.45 or below 0.45 respectively.
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the murine APOBEC3 did not alter MHV68 replication and
pathogenesis.
Results
APOBEC3 hotspots are prevalent in herpesvirus genomes
In a single report outlining the impact of APOBEC3 cytidine
deaminase on herpesviruses, HSV-1 replication was reduced 4–10
fold upon transient expression of hA3C. In addition, hyperedited
HSV-1 and EBV sequences consistent with hA3 deamination were
detected in patient samples using a sensitive, but non-quantitative
PCR detection method (Suspene et al., 2011). However, the natural
occurrence of APOBEC3-mediated cytidine deamination and the
consequence of this selective pressure are not known. We utilized
an in silico approach to predict the distribution of APOBEC3 recogni-
tion sites in herpesvirus genomes. The ‘hotspot’ or consensus
recognition sequence is TC (where the underlined C represents the
targeted cytidine) for hA3A, hA3B, hA3F and hA3H (Hultquist et al.,
2011; Liddament et al., 2004; Senavirathne et al., 2012; Yu et al.,
2004; Zheng et al., 2004) TTC for hA3C (Taylor et al., 2013), CCC for
hA3G (Jern et al., 2009), and TCC for mA3 (MacMillan et al., 2013). To
determine whether particular A3 hotspot motifs were over- or
under-represented throughout the viral genomes we measured the
frequency of each A3 hotspot motif (TC, TTC, CCC and TCC) within a
1 kb sliding window across each genome at intervals of 100 nt. The
observed frequencies in each window were then compared to a null
model based on randomly shufﬂed versions of that genome
sequence, allowing us to statistically evaluate overrepresentation
and underrepresentation.
Viruses that are susceptible to various A3 enzymes would likely
have evolved to limit hotspot motifs in their genomes. Viruses that
do not encounter certain A3 proteins or those with a viral
countermeasure might have an overrepresentation of motifs in
their genomes, especially if they have evolved under pressures to
avoid a different A3 protein. For example, under-representation of
TTC (the motif for hA3C) will increase the relative frequency of
motifs such as CCC (the motif for hA3G) assuming that there are no
additional selective pressures against the other motifs. We eval-
uated the predictive ability of our model by examining the
APOBEC3 hotspot distribution in human papilloma virus 16
(HPV16). HPV genomes are targets for deamination upon over-
expression of hA3A, hA3C, and hA3H, and mutation signatures that
are consistent with deamination at TC hotspots are detected by a
sensitive PCR assay in clinical wart specimens (Vartanian et al., 2008).
Human A3A, hA3B and hA3H are expressed in dermal epithelial cells,
the preferred site of infection and viral replication of HPV (Madsen
et al., 1999; OhAinle et al., 2006; Quinlan et al., 1984; Trivedi et al.,
2006). Taken together, HPV is subjected to the selective pressures of
hA3s with TC hotspots (Vartanian et al., 2008). In agreement, our
computational analysis determined that TC hotspots were largely
underrepresented in the HPV genome (Fig. 1A). This depletion of TC
hotspots in the genome is consistent with evasion from the antiviral
pressures of hA3A, hA3B, hA3F or hA3H (A3A/A3B/A3F/A3H). More-
over, the HPV genome had an underrepresentation of TTC hotspots
favored by the ubiquitously expressed hA3C. In contrast, the HPV
genome was largely neutral with some enrichment for CCC hotspots
recognized by hA3G, which is expressed predominantly in lympho-
cytes, a cell type not known as a reservoir for HPV. Finally, the HPV
genome was predominately neutral with some occurrences of mA3
hotspot-enriched regions. This is consistent with a human pathogen
that would not have been under selective pressure to limit mA3 sites
in the genome.
We next applied this analysis to multiple human herpesviruses
and MHV68. As depicted in Fig. 1A, we found that the genomes of
the alphaherpesviruses HSV-1 and VZV were enriched for A3G
hotspots. These genomes were largely neutral or even under-
represented for A3A/A3B/A3F/A3H hotspots. Depletion of hotspots
for A3A/A3B/A3H expressed at high levels in epithelial cells is
consistent with selective pressure to limit recognition of virus that
replicates in the dermal epithelium, yet a ﬁnding of enrichment for
A3G in the VZV genome was unexpected given its T lymphocyte-
associated viremia (Zerboni et al., 2014). Within the betaherpes-
viruses, the HCMV genome had regions overrepresented with A3A/
A3B/A3F/A3H and A3C hotspots, but was largely underrepresented
for A3G. The HHV-6A genome was also enriched for A3A/A3B/A3F/
A3H and A3C hotspots. While the betaherpesviruses were largely
depleted or neutral for A3G, the genomes of the gammaherpes-
viruses that are also lymphotropic were enriched for A3G hotspots.
The EBV and KSHV gammaherpesvirus genomes were underrepre-
sented for A3A/A3B/A3F/A3H hotspots. The MHV68 genome was
largely neutral for APOBEC3 hotspots with a higher representation of
hA3G and mA3 hotspots. With the exception of HCMV, mA3 sites
were overrepresented in each human herpesvirus genome analyzed.
In Fig. 1B, the heatmap representation of the percentage of over-
represented regions (left panel) and underrepresented regions (right
panel) in the genomes of each human herpesvirus and MHV68
illustrates similar trends in the proﬁle of human andmouse APOBEC3
hotspots among members within the subfamilies. Lastly, we exam-
ined the distribution of hotspots in the MHV68 genome. With the
exception of the internal repeats at nt positions 26,778–28,191 and
98,981–101,170, the regions of overrepresented hotspots were evenly
distributed along the MHV68 genome (Fig. 1C). Taken together, our
analysis predicts that some herpesvirus genomes are targets of
APOBEC3 deamination.
Human APOBEC3 restriction of MHV68 replication
Given the identiﬁcation of A3 hotspots in the MHV68 genome, we
next examined the impact of A3 expression on lytic replication. We
co-transfected A3 expression constructs with infectious MHV68þ
BAC DNA that encodes the YFP marker to monitor viral replication by
ﬂuorescent microscopy. Expression of hA3A limited the infection to
single YFPþ cells (Fig. 2, top panel). In contrast, co-transfection of the
empty vector or the A3A E72A active site mutant resulted in foci of
10–20 YFPþ cells, indicating no impairment of virus spread. Expres-
sion of wild type mA3 did not impair the formation of YFPþ foci in
the infection (Fig. 2, bottom panel).
These observations of virus restriction by hA3 but not mA3
were conﬁrmed and extended to other human APOBEC3s upon
quantitation of virus yield by plaque assay (Fig. 3A). Human A3A
inhibited viral replication by nearly 4 logs while co-transfection
with hA3B and hA3C proteins resulted in a 2.5 log-fold reduction
in replication. Co-transfection of either hA3DE or hA3H resulted in
a lesser 5-fold reduction in virus output while hA3F and hA3G did
not impair MHV68 replication. In agreement with our previous
observation that mA3 overexpression did not impact virus spread
in the culture, co-transfection with mA3 did not impact MHV68
yield (Fig. 3B). Expression of the human and mouse APOBEC3
proteins was veriﬁed by immunoblot (Fig. 3A and B, respectively).
We conclude that hA3A, hA3B and hA3C are restrictive against
MHV68 while mA3 is not.
Human APOBEC3 restriction of MHV68 replication is dependent
on A3 active sites
Given the observation that several human APOBEC3 proteins
impair MHV68 replication, we next examined if APOBEC3 enzymatic
activity is required by comparing restriction of MHV68 by the WT
and active site mutant forms of hA3A and hA3B. Similar to other
APOBEC proteins, A3 enzymes have retained a conserved active site
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sequence consisting of His-X-Glu-X23–28-Pro-Cys-X2–4-Cys. The histi-
dine and cysteine residues coordinate a zinc ion while the glutamic
acid serves as a proton shuttle in catalysis (Cullen, 2006). Mutation of
either the cysteine or the glutamic acid abolishes the cytidine
deaminase function of A3 enzymes (Hakata and Landau, 2006;
Narvaiza et al., 2009). The hA3A E72A active site mutant did not
restrict MHV68 yield compared to WT hA3A (Fig. 4A). Restriction by
hA3B was lost with the N-terminal E68A single active site mutant
and the E68A/E255A double mutant. However, the C-terminal single
hA3B E255A mutant retained restrictive function by reducing virus
yield by 4.5-fold, albeit 56% less than the WT hA3B (Fig. 4A). The
changes in restrictionwere not attributed to differences in expression
levels of the WT and active site hA3 mutants (Fig. 4A, lower panel).
Since hA3A reduced MHV68 DNA copy number by greater than 50-
fold compared to the empty vector and A3A E72A mutant controls
(Fig. 4B), we examined two regions of the MHV68 genome for C to T
or G to A transition mutations. In samples derived from A3A and A3B
cotransfections, the incidence of mutation was extremely low
in 18 and 11 respective clones of a GC-rich region of the genome
(bp 69,873–70,761) and 24 and 23 respective clones of a second
region of the genome that is enriched for TC hotspots (bp 88,884–
89,613) (Table 1). While three transition mutations were observed for
region two in A3A-restricted samples, these led to silent or con-
servative aa changes. We also found a similar number of transition
mutations in the viral DNA of samples derived from the empty
control vector cotransfections. The mean mutation frequency for
MHV68-infected samples restricted by A3A (0.15%) and A3B (0.06%)
contrasts sharply with the mutation frequencies reported for HSV-1
and EBV (6–20% by Suspene et al. 2011) and hepatitis B virus (25–50%
by Vartanian et al. 2008). Taken together, the active sites of hA3A and
hA3B are required for MHV68 restriction, but we found no strong
evidence for hA3A or hA3B deamination of the genome.
Human APOBEC3 restriction of MHV68 replication is lost upon de
novo infection
Several human APOBEC3 proteins were identiﬁed as potent
inhibitors of MHV68 replication, the nuclear localized hA3B
Fig. 2. Restriction of MHV68 spread by human APOBEC3A, but not murine APOBEC3. HEK 293T cells were cotransfected with MHV68-H2bYFP BAC and the indicated human
(hA3) and murine (mA3) APOBEC3 constructs and virus spread was visualized by ﬂuorescence microscopy (upper panels) and bright ﬁeld microscopy (lower panels) 48 h
later. HA3A E72A is an active site mutant of human A3A. MA3 E73A and mA3 E253A are active site mutants of mA3. Images shown are cropped ﬁelds of pictures taken at
20 magniﬁcation. The images of MHV68-H2bYFPþ foci were false-colored green.
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(Lackey et al., 2012), the predominantly cytoplasmic hA3DE
(Kinomoto et al., 2007), and hA3A, hA3C and hA3H, which shuttle
between the nucleus and cytoplasm (Bogerd et al., 2006; Kinomoto
et al., 2007; Li and Emerman, 2011). The MHV68 genome delivered
by transfection would likely be susceptible to APOBEC3s in both the
nucleus and cytoplasm. However, we reasoned that the encapsi-
dated genome would be protected from cytoplasmic A3s in a de
novo infection with intact particles. As such, we transfected the
panel of APOBEC3 constructs one day prior to infection with
MHV68 at a multiplicity of infection (MOI) of 0.01. We unexpectedly
found that the APOBEC3 proteins with potent restrictive function in
the co-transfection experiment were no longer restrictive against
infection initiated by virion particles (Fig. 5). Thus, the method of
viral genome delivery and initiation of lytic infection inﬂuences the
restrictive capacity of the APOBEC3 enzymes. This suggests that
either compartmentalization of the herpesvirus genome or counter-
functions imparted by virion-associated factors result in a replica-
tive process that is impervious to antiviral APOBEC3 function.
Murine APOBEC3 does not impact MHV68 replication in vivo
Murine A3 overexpression in 293Tcells did not signiﬁcantly restrict
MHV68 replication. However transient expression studies cannot be
relied upon as an absolute indicator of the capacity of an antiviral
molecule to restrict a pathogen in the host. Thus, we determined the
impact of murine A3 on MHV68 pathogenesis in mice with a
disruption in the mA3 gene (Fig. 6A). The galactosidase-neomycin
fusion (β-geo) stop cassette that is inserted between exons IV and V
of mA3 in murine APOBEC3 knock-out mice (mA3 / mice) was
conﬁrmed by PCR and amplimer sequencing (Fig. 6B). Additionally,
mA3 protein was not detected in the spleens or thymus of mA3 /
mice (Fig. 6C). Okeoma et al. (2007) previously generated mA3 /
mice as described here; a truncated protein in mA3 / tissues was
not observed. Furthermore, a truncated mA3 protein generated from
exons 1–4 upon in vitro expression was devoid of deaminase
function (Okeoma et al., 2007).
Infection of mice with MHV68 by intranasal inoculation is
followed by a period of acute replication in the lung. To examine
the inﬂuence of mA3 on acute replication, the levels of virus
replication in the lungs of infected WT or mA3 / mice were
measured at 4 and 7 dpi. Although there is a slight, non-
statistically signiﬁcant difference between the two groups
at 4 dpi, viral titers were indistinguishable between WT and
mA3 / mice at 7 dpi, indicating that the loss of murine APOBEC3
did not enhance MHV68 replication in the lung (Fig. 6D).
Active MHV68 replication is typically cleared from the lung
within two weeks prior to virus dissemination to the spleen.
MHV68 establishes a latent infection primarily in B cells of the
spleen with the peak of latency 16–18 dpi, a timepoint closely
corresponding to germinal center expansion (Weck et al., 1996,
1999a). We observed a robust two-fold increase in splenomegaly
as expected, yet there was no difference between the degree of
splenic expansion in the infected WT and mA3/ mice. To
examine whether loss of mA3 would impact latency establishment
Fig. 3. Restriction of MHV68 replication by human APOBEC3. (A) Variable restriction by human APOBEC3 constructs as measured by plaque assay 48 h after HEK 293T cells
were cotransfected with infectious MHV68-H2bYFP BAC DNA and the indicated APOBEC3 constructs. (B) Murine A3 did not signiﬁcantly impair MHV68 replication in
HEK293Ts. Below each bar graph, immunoblots using antibodies against the indicated epitopes were used to validate APOBEC3 expression. Lysates from the empty vectors
pcDNA3.1 (control vector for hA3B-hA3H) and pcDNA6 (control vector for hA3A and hA3C) were included in each blot and revealed no speciﬁc signal. Bars represent the
mean7standard deviation of three replicates (A) and ﬁve replicates (B); *pr0.05 and **pr0.005.
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in the spleen 16 dpi, intact splenocytes were analyzed by a limiting
dilution PCR assay to determine the frequency of viral genome
positive cells. MHV68 established equivalent levels of latency in
the spleens of WT (1/156) and mA3 / mice (1/128) (Fig. 6F). The
frequency of intact splenocytes that spontaneously reactivated
was examined by the observation of CPE upon explant and
coculture with MEFs in a limiting dilution reactivation assay. Loss
of mA3 had an insigniﬁcant two-fold impact on MHV68 reactiva-
tion, with splenocytes from infected WT mice and infected
mA3/ mice reactivating at frequencies of 1/19,074 and
1/10,966 cells, respectively (Fig. 6G). Moreover, this slight differ-
ence in reactivation at 16 dpi had no effect on the maintenance of
the frequency of genome positive cells later during chronic
infection at 42 dpi (data not shown). Taken together, the absence
of mA3 did not impact any aspect of MHV68 pathogenesis up to six
weeks following an intranasal infection.
Discussion
Targets of human APOBEC3 deaminase activity have been recently
expanded to include plasmid DNA (Stenglein et al., 2010), small DNA
viruses (Chen et al., 2006) and the large human herpesviruses
(Suspene et al., 2011). In this study, we set out to determine if the
single APOBEC3 protein, mA3, encoded by the mouse had the ability
to restrict the rodent herpesvirus pathogen MHV68. Our in silico
analysis determined that A3 sites were abundant in MHV68, implying
that this genome would be susceptible to A3 mediated deamination.
Overexpression of mA3 together with infectious herpesvirus DNA did
not signiﬁcantly impact MHV68 titers compared to a more substantial
restriction observed with hA3s. Surprisingly, the hA3 restriction was
lost upon de novo infection. WT and mA3/ C57BL6 mice were
indistinguishable in the levels of acute MHV68 replication in the lung,
latency establishment in the spleen and reactivation from the spleen.
Thus, loss of mA3 had no discernable effect on MHV68 replication
in vivo.
In this study we identiﬁed several human APOBEC3s as potent
restrictors of MHV68 replication. Additionally, we found that the
restriction by hA3A and hA3B is dependent on their previously
identiﬁed active sites (Hakata and Landau, 2006; Stenglein et al.,
2010). Interestingly hA3B restriction of MHV68 was absolutely
dependent on the N-terminal amino acid, E68 and less dependent
on the C-terminal E255 residue, possibly indicating a separation of
function between the E68 and E255 active sites. The requirement
Fig. 4. APOBEC3A and APOBEC3B active sites are required for restriction of viral replication and viral DNA synthesis. (A) Loss of restriction by mutant human APOBEC3A
(hA3) and APOBEC3B (hA3B) constructs as measured by plaque assay and quantitative PCR (hA3B) 48 h after HEK 293T cells were cotransfected with infectious MHV68-
H2bYFP BAC DNA and the indicated APOBEC3 constructs. Below each bar graph, immunoblots using antibodies against the indicated epitopes were used to validate APOBEC3
expression. Lysates from the empty vectors pcDNA6 (control vector for WT and mutant hA3A) and pcDNA3.1 (control vector for WT and mutant hA3B) were included in each
blot and revealed no speciﬁc signal. Bars represent the mean7standard deviation of three replicates; *pr0.05 and **pr0.005. (B) Quantitation of MHV68 genomes by qPCR
analysis of DpnI-digested DNA. DNA levels were normalized to levels upon cotransfection with the empty vector, pCDNA6; *pr0.05 and **pr0.005.
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for these hA3 active sites to restrict MHV68 growth and DNA
replication is consistent with deamination of the genome as the
basis of restriction. However, we have no direct evidence to
support this hypothesis since DNA from A3A or A3B cotransfec-
tions contained few C to T or G to A transitions. Although two
transitions were present in A3A cotransfected samples, we
observed a similar frequency of transitions in DNA from control
transfections. The lack of a high mutation frequency in the A3A
samples might be attributed to heavily deaminated DNA that
is unable to serve as a template for replication or rare events
that are below the limit of detection. Alternatively, A3A might
impair MHV68 replication using a deamination-independent
mechanism that is dependent on the active site. For example,
A3A mutants that were deaminase defective but retained other
known functions such as DNA binding and localization to the
nucleus were found to restrict parvoviruses (Chen et al., 2006;
Narvaiza et al., 2009).
We hypothesized that in silico analysis would reveal a hotspot
proﬁle for a herpesvirus that reﬂects tropism for cell types that
express high levels of particular host APOBEC3s. Namely, virus
genomes under selective pressure by one or more APOBEC3s would
be underrepresented or depleted of that particular APOBEC hotspot.
The HPV genome is depleted of A3A/A3B/A3H hotspots and neutral
or enriched for hA3G, consistent with its epithelial cell tropism.
However, the association of cell tropism and hotspot proﬁles was not
as straightforward for the herpesviruses. Human herpesviruses such
as VZV, EBV, and KSHV that reside in lymphocytes during their life
cycle were not depleted for A3G hotspots. The VZV genome was
depleted for A3A/A3B/A3H hotspots, yet HSV-1, another virus that
replicates in the epithelium was predominately neutral with over-
representation in some regions. The overrepresentation of TC and
TTC hotspots in the HSV-1 genome is consistent with the restriction
of HSV-1 replication by the ectopic expression of hA3A and hA3C
reported by Suspene et al. (2011). Interestingly, this study reported a
high incidence of edited HSV-1 genomes upon transient transfection
of hA3C and a striking frequency of hypereditied HSV-1 and EBV
genomes in clinical specimens. These ﬁndings relied on the detection
of rare deamination events by PCR based ampliﬁcation at low
denaturing temperatures (Suspene et al., 2011). A non-biased quan-
titative determination of the incidence of herpesvirus deamination in
human infections and the impact on pathogenesis warrants further
investigation.
Table 1
Analysis of mutations arising in the viral genome upon cotransfection with human APOBEC3A or APOBEC3B.
Experimenta Number of clonesb Mutation frequencyc SNPd, genomic coordinatee
Region 1 (bp 69,873–70,761)
APOBEC3A 18 0.008%, 1/12,492 T-C 70,265
APOBEC3B 11 0%; 0/5,269
Empty vector 11 0%; 0/7,634
Region 2 (bp 88,884–89,613)
APOBEC3A replicate 1 6 0.14%; 6/4,086 A-G 88,939
T-C 89,050, G-A 89,230
A-G 89,191
A-G 89,283, A-G 89,286
APOBEC3A replicate 2 9 0.16%; 9/5,526 C-T 89,033f, A-G 89,178
G-A 89,083f
T-C 89,248, T-C 89,270
T-C 89,293
A-G 89,308
T-C 89,407
A-T 89,450
APOBEC3A replicate 3 9 0.16%; 8/5,148 A-G 88,985
T-C 89,197
A-G 89,207, T-C 89,417
A-C 89,320
A-G 89,352
A-G 89,357
A-G 89,434
APOBEC3B replicate 1 7 0.09%; 4/4,417 A-G 89,103, T-C 89,236
A-G 89,495, T-C 89,507
APOBEC3B replicate 2 7 0%; 0/4,921
APOBEC3B replicate 3 8 0.09%; 5/5,416 T-C 89,100, A-G 89,106
T-C 89,234
A-G 89,265
T-C 89,286
Empty vector replicate1 7 0.14%; 7/4893 T-C 89,050
A-G 89,083, T-C 89,419
T-C 89,432, T-C 89,499, C-T 89,587f
T-C 89,500
Empty vector replicate 2 11 0.10%; 7/6699 T-A 88,908
G-A 88,926f, A-G 89,936, A-G 89,506
G-A 89,083f
A-G 89,481
T-C 89,498
Empty vector replicate 3 6 0.08%; 3/3774 A-G 89,127, A-G 89,199, A-G 89,287
a Cotransfection of MHV68 genomic BAC DNA with the identiﬁed construct.
b Number of independent clones sequenced for mutation analysis.
c Mutation frequency is calculated as follows: (number of changes/total number of nucleotides sequenced per experiment)100.
d SNP – single nucelotide polymorphism.
e Position of SNP in the MHV68 genome.
f SNPs that reﬂect transition mutations (G to A or C to T changes).
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At this juncture, the APOBEC3 hotspot analysis has some pre-
dictive value and correlates with some aspects of herpesvirus
biology, but an interpretation of hotspot frequencies is more complex
since a multitude of factors apply evolutionary pressures. The
occurrence of a particular dinucleotide or trinucleotide sequence is
inﬂuenced by codon bias, a wide expanse of protein–DNA interac-
tions, and restrictive pressures by one APOBEC3 deaminase that may
in turn bias the incidence of another hotspot. These pressures are
further compounded by the fact that each herpesvirus engages
multiple cell types in its life cycle and, as discussed below, these
viruses may have evolved countermeasures.
Strikingly, hA3 restriction of MHV68 replication was observed
upon transfection of nonencapsidated infectious DNA but was lost
upon de novo infection with virion particles. MHV68 virions may
deliver a factor that counteracts the hA3 proteins. Tegument proteins
from several herpesviruses families function in either the cytoplasm
or the nucleus to limit the antiviral response from the host. KSHV
ORF45 inhibits type I interferon signaling by impairing the phosphor-
ylation and nuclear translocation of IRF-7 (Sathish and Yuan, 2011;
Zhu et al., 2002). HSV1 ICPO, HCMV pp71, HVS ORF3, EBV BNRF1 and
MHV68 ORF75C translocate to the nucleus upon virus infection to
degrade or relocalize components of the antiviral nuclear domain 10
structures (ND10) (Boutell and Everett, 2013; Full et al., 2012; Ling
et al., 2008; Penkert and Kalejta, 2012; Sewatanon and Ling, 2013; Tsai
et al., 2011). We did not ﬁnd signiﬁcant homology of MHV68 virion
components including glycoproteins, tegument and capsid proteins to
known A3 antagonists. However, we cannot rule out the existence of a
novel mechanism by which the virion structural components or even
RNA molecules mediates resistance to APOBEC3 proteins.
The loss of MHV68 restriction might also be explained by the
compartmental separation of A3 proteins from the MHV68 gen-
ome in a natural course of infection. Several of the hA3 proteins
that exhibit restriction of MHV68, namely hA3A, hA3B, hA3C and
hA3H are targeted to the nucleus (Bogerd et al., 2006; Kinomoto
et al., 2007). We propose that the hA3 proteins might be separated
from viral replication centers in the nucleus via either the direct
action of a viral factor or indirectly due to viral remodeling of the
nucleus. Herpesvirus replication, transcription and the formation
of viral capsids transpires in intranuclear structures known as
replication centers that are deﬁned by the presence of key viral
replication proteins as well as host proteins (de Bruyn Kops and
Knipe, 1994; Quinlan et al., 1984; Weller, 2010). Nuclear substruc-
tures such as the ND10, as well as nuclear protein localization and
abundance are tightly regulated by herpesviruses to maintain
optimal viral gene expression and replication (Saffert and
Kalejta, 2008). The subcellular localization of A3 proteins and
herpesvirus replication compartments could provide mechanistic
insight for viral evasion of hA3 restriction.
Several human APOBEC3 proteins exhibit restriction of MHV68
replication, but mA3 exhibited no restrictive capacity in the
cotransfection experiments. This lack of restriction with mA3
overexpression is not likely due to the absence of a co-factor in
the HEK 293T cells. Murine APOBEC3 partially restricts Moloney
murine leukemia virus replication and restricts HIV-1 lacking Vif
to similar levels as hA3G in 293T cells (Doehle et al., 2005;
Sanchez-Martinez et al., 2012). The absence of restriction with
overexpressed mA3 was supported by a lack of enhancement in
MHV68 pathogenesis in mA3 knockout mice. Thus, MHV68 might
encode a mA3 antagonist that signiﬁcantly limits antiviral APO-
BEC3 activity such as HIV Vif (Malim, 2009; Malim and Emerman,
2008; Mariani et al., 2003) or Murine Leukemia Virus (MLV) glyco-
gag (Stavrou et al., 2013). Additionally, a recent report identiﬁed a
signiﬁcant role for host uracil DNA glycosylase (UNG) in reducing
the effect of hA3G-induced hyperediting of duck hepatitis B virus
(Kitamura et al., 2013). MHV68, like other herpesviruses encodes a
uracil DNA glycosylase (UNG/ORF46). However, we did not observe
an increased restriction of MHV68 replication by hA3A, hA3B or
mA3 in cells infected with a recombinant MHV68 harboring a stop
codon in ORF46 compared to the control repair virus (Minkah,
Chavez, and Krug, unpublished results).
Infection of mice lacking mA3 did not lead to an enhancement of
MHV68 pathogenesis. This may be attributed to a viral counter-
measure as described above, a lack of mA3 antiviral function in the
context of a herpesvirus infection or a yet undiscovered role in
a particular aspect of chronic infection in this pathogenesis model.
The intranasal route of inoculation is characterized by high levels of
productive replication in the lungs, a tissue with lower mA3 expres-
sion levels (Mikl et al., 2005). MA3 protein is expressed at high levels
in the spleens, but its absence did not inﬂuence latency establish-
ment in the spleen or reactivation from latency. Another route of
infection, such as intraperitoneal inoculation might reveal the
importance of MHV68 replication in peritoneal exudate cells wherein
the primary latency reservoir is macrophages (Weck et al., 1999b).
Indeed, the inﬂuence of some host proteins such as promyelocytic
leukemia nuclear bodies (PML) (Sewatanon et al., 2013) or viral
proteins such as M1 and M2 on MHV68 pathogenesis is dependent
on the route of infection (Clambey et al., 2000; Jacoby et al., 2002).
Finally, it is possible that another APOBEC protein compensates for
the loss of mA3 to limit MHV68 replication. A hyperediting signature
similar to murine APOBEC1 deamination was reported in a mouse
model of hepatitis B virus infection (Petit et al., 2009; Renard et al.,
2010). Furthermore, in a rat model of HSV-1-induced encephalitis,
APOBEC1 levels were increased upon HSV-1 infection and over-
expression of APOBEC1 both enhanced hyperediting of HSV-1
genomes and reduced viral titers (Gee et al., 2011).
Fig. 5. Loss of APOBEC3 restriction in the context of de novo infection with virus
particles. HEK 293T cells were transfected with the indicated APOBEC3 constructs
24 h prior to de novo infection with MHV68-H2bYFP virus. MHV68 replication was
measured by plaque assay 48 hpi. Below each bar graph, immunoblots using
antibodies against the indicated epitopes were used to validate APOBEC3 expres-
sion. Lysates from the empty vectors pcDNA3.1 (control vector for hA3B, hA3DE-
hA3H) and pcDNA6 (control vector for hA3A and hA3C) were included in each blot
and revealed no speciﬁc signal.
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MHV68 infection of mice provides a tractable model pathogen-
esis system to dissect the contribution of virus and host factors
that inﬂuence chronic gammaherpesvirus infection. Primates have
diversiﬁed their repertoire of A3 cytidine deaminases under the
selective pressure of retroelements and viral pathogens. We
sought to examine whether the evolutionary distinct yet ‘primor-
dial’ APOBEC3 encoded by mice shared the restrictive property of
the expanded human APOBEC3 molecules against MHV68, with
the aim of utilizing mA3 / mice as a platform for pathogenesis
and mechanistic investigations. However, mA3 did not restrict
MHV68 replication in cell culture or pathogenesis in mice. The
unexpected loss of the hA3 restrictive phenotype when replication
was initiated upon de novo infection with virus particles leads us
to posit that herpesviruses are largely protected from hA3 restric-
tion. Possible evasion mechanisms to explore include a virion-
associated countermeasure such as a tegument protein or a block
in APOBEC3 access to the viral genome either due to encapsidation
of the viral genome during cytoplasmic transport to the nucleus or
compartmentalization of the genome in nuclear replication
centers.
Materials and methods
Viruses, cells and mice
The recombinant marking virus, MHV68-H2bYFP was used
the for cell-culture experiments. This virus encodes a histone 2b
(H2b)-enhanced yellow ﬂuorescent protein (eYFP) fusion protein
that tethers the YFP protein to nucleosomes and eliminates the
passive diffusion of the ﬂuorescent YFP signal out of the nucleus to
enhance infected cell imaging by microscopy (Collins and Speck,
2012). Mice were infected with MHV68 WUMS (ATCC VR1465) as
the wild-type virus. Virus passage and titer determination were
performed as previously described (Weck et al., 1996, 1999a).
Human epithelial kidney cells (HEK 293T) were maintained in
Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with
10% fetal bovine serum, 1% penicillin, and streptomycin at 37 1C in
5% CO2. Murine ﬁbroblast cells (NIH 3T12) were maintained in
Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with
8% fetal calf serum, 100 U of penicillin per ml and 100 mg of
streptomycin per ml at 37 1C in 5% CO2
Murine APOBEC3 knock-out (mA3 /) mice were generated by
blastocyst injection of 129P2/OlaHsd embryonic stem cell clone
XN450 (Baygenomics, San Francisco) that contained an 8 kb
galactosidase-neomycin fusion (β-geo) gene trap insertion retro-
viral vector between exons 4 and 5 of mA3. The mice were crossed
for several generations onto a C57/Bl6 background and genotyped
by PCR using primers spanning the insertion site. The WT
genotype was ampliﬁed with primer 21 (50 CTGTAACCTGG-
TATCTCCCGTC 30) and primer 22 (50 GGAAAAACTGCTTGCCAGGCTC
30). The mA3/ genotype was ampliﬁed with primer 21 (50
CTGTAACCTGGTATCTCCCGTC 30) and primer 23 (50 CACAAGGTT-
CATATGGTGCCGT 30). The mA3 / mice and their WT C57BL6
counterparts were maintained at the Stony Brook University
Division of Laboratory Animal Research (DLAR) facility in
Fig. 6. Absence of murine APOBEC3 does not alter MHV68 pathogenesis. (A) Schematic depicting the disruption of murine APOBEC3 (mA3) by the insertion of a β-geo
cassette to generate mA3 knockout mice (mA3 /). (B) Genotype PCR analysis of DNA harvested from the splenocytes of infected WT C57BL/6 or mA3/ mice. The locations
of primers for either the WT or mutant mA3 gene are shown in panel A. (C) Immunoblot demonstrating expression of mA3 in WT but not mA3/ mice. (D) Acute replication
in the lungs of WT or mA3 / lungs 4 and 7 days post-intranasal infection with 1000 PFU of WT MHV68. (E) Spleen weights from naïve WT, infected mA3 / mice or
infected WT mice 16 dpi. (F) Latency is determined as the frequency of viral genome positive splenocytes determined by limiting dilution PCR. (G) Frequency of reactivation
from intact splenocytes determined by a limiting dilution explant reactivation assay 16 dpi. Open symbols represent preformed infectious virus from mechanically disrupted
cells plated in parallel. The data shown represent three independent experiments with splenocytes pooled from three to ﬁve mice per experimental group.
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accordance with protocols approved by the Institutional Animal Care
and Use Committee of Stony Brook. Eight- to twelve-week old WT
and mA3/ mice were infected intranasally with 1000 PFU of
MHV68 under isoﬂurane anesthesia. At the indicated times post-
infection, organs were harvested and processed as described below.
Transfections
For transient co-transfections, 4105 HEK 293T cells were
seeded per well of a 12-well tissue culture plate one day prior to
transfection with 2.5 μg of APOBEC3 expression plasmids and
1.55 μg of MHV68 BAC DNA. All transient co-transfections were
performed using TransIT-LT1 Transfection Reagent according to
the manufacturer0s instructions (Mirus, Madison WI). Forty-eight
hours later, the cells were subjected to multiple freeze–thaw
cycles to release infectious virus that was then titered by plaque
assay on a NIH 3T12 cell monolayer.
For the transfection followed by infection experiments, HEK
293T cells were transfected with the desired human and mouse
APOBEC3 proteins as outlined above. Twenty-four hours post-
transfection, cells were infected with MHV68-H2bYFP virus at an
MOI of 0.01. Forty-eight hours after the infection virus output was
quantiﬁed by a plaque assay.
Fluorescence microscopy
Virus infection with MHV68-H2bYFP was visualized by ﬂuor-
escence microscopy. Imaging was performed with a Zeiss Axiovert
S100 inverted microscope (Carl Zeiss Microscopy GmbH, Jena
Germany) equipped with a Luminera INFINITY 3-1UR 1.4 mega-
pixel low light CCD digital camera (Lumenera, Ottawa ON Canada).
Images were analyzed using Axiovision Software (Axiovision LE
Rel.4.3, Carl Zeiss Microscopy GmbH, Jena Germany).
Plaque assay
1.8105 NIH 3T12 cells were seeded per well in a 6-well tissue
culture plate one day prior to infection. The next day, the NIH 3T12
cells were infected with serial dilutions of cell homogenate and
overlayed with 1.5% methylcellulose in DMEM containing 5% FBS.
One week later, the methylcellulose was removed and cells were
washed twice with PBS prior to methanol ﬁxation and staining
with a 0.1% crystal violet solution in 10% methanol.
Immunoblot
Total protein lysate was harvested in lysis buffer (150 mM
sodium chloride, 1.0% IGEPAL CA-630, 0.5% sodium deoxycholate,
0.1% sodium dodecyl sulfate, 50 mM Tris pH 8.0) supplemented
with a protease inhibitor cocktail (Sigma, St. Louis MO). Fifty
micrograms of each lysate were separated in a 12% SDS PAGE gel
and transferred onto polyvinylidene ﬂuoride (PVDF) membrane.
APOBEC3 proteins were detected using a mouse monoclonal
antibody speciﬁc for the HA-epitope (Cell signaling, Danvers MA)
on mA3, A3B, A3C, A3F, and A3G constructs, a V5 epitope (Santa
Cruz biotechnology, Dallas Texas) for A3DE and a rabbit mono-
clonal speciﬁc for human A3A (Hakata and Landau, 2006). A rabbit
monoclonal antibody to human glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) was used as a loading control. HRP-conjugated
secondary antibodies were detected using an enhanced chemilu-
minescence reagent (ECL, Thermo Scientiﬁc, Waltham MA).
Quantitative PCR
Total cell DNA from the co-transfection experiments was
column-puriﬁed (Qiagen, Limburg, Netherlands) and digested
with 20 units of Dpn1 (New England Biolabs, Ipswich MA) for
12 h at 37 1C to remove input MHV68 BAC DNA. One ng of DpnI-
digested DNA was input into a quantitative PCR reaction (Quanta
Biosceinces- Perfecta SYBR GREEN, Gaithersburg MD) using pri-
mers speciﬁc to a region of MHV68 ORF12 (forward primer,
50 GTCTACAACAGGATCTGCATTT 30, reverse primer 50 AAAACTC-
TACCGTGACTGTGAA 30) and primers for human GAPDH (forward
primer, 50 GTATGACTGGGGGTGTTGGG 30, reverse primer 50
GCGCCCAATAGGACCAAATC 30). The relative level of viral genome
copy number was determined by ΔΔCt.
Sequencing
Total cell DNA from the co-transfection experiments was
extracted as outlined above. The DNA was digested with 20 units
of Dpn1 (New England Biolabs, Ipswich MA) for 12 h at 37 1C to
remove input MHV68 BAC DNA. Two regions in the MHV68
genome (bp 69,873–70,761 and bp 88,884 to 89,613) were ampli-
ﬁed with Dynazyme II DNA polymerase (Thermo Scientiﬁc,
Waltham MA), cloned into the TOPO TA cloning vector (Life
Technologies, Carlsbad, CA) and sequenced to identify mutations
that arose during infection.
Pathogenesis
For acute titers, the right and left lungs of mice were removed
4 and 9 days post-infection and disrupted with a Mini-Beadbeater
(Biospec, Bartlesville OK). The homogenates were titered by
plaque assay. Spleens were harvested to determine viral latency
establishment and reactivation from latency 16 dpi.
To determine the frequency of cells harboring the viral genome,
a single cell suspension of splenocytes was prepared and analyzed
by limiting dilution PCR. Six, three-fold serial dilutions of spleno-
cytes were plated in a 96-well PCR plate in a background of NIH
3T12 cells and lysed overnight at 56 1C with Proteinase K. The plate
was then subjected to an 80-cycle nested PCR with primers
speciﬁc for MHV68 ORF50. Twelve replicates were analyzed at
each serial dilution and plasmid DNA at 0.1, 1 and 10 copies was
included to verify the sensitivity of the assay.
To determine the frequency of cells harboring latent virus
capable of reactivation upon explant, single cell splenocytes were
prepared from mice 16 dpi, resuspended in DMEM containing 10%
fetal bovine serum and plated in twelve serial two-fold dilutions
onto a monolayer of mouse embryonic ﬁbroblast (MEF) cells
prepared from C57BL6J mice in 96-well tissue culture plates.
Twenty-four replicates were plated per serial dilution. The wells
were scored for cytopathic effect (CPE) two to three weeks after
plating. To differentiate between pre-formed infectious virus and
virus spontaneously reactivating upon cell explant, parallel sam-
ples were mechanically disrupted using a Mini-Beadbeater prior to
plating on the monolayer of MEFs to release preformed virus that
is scored as CPE.
Bioinformatic analysis
To measure under- and over-representation of APOBEC3 hot-
spots, we compared the observed frequency of each APOBEC
consensus motif (TC for hA3A, hA3B, hA3F and hA3H, TTC for
hA3C, CCC for hA3G and TCC for mA3) to a random expectation
null model. To assess the effects throughout the viral genomes we
used sliding 1 kilobase windows to scan each genome at intervals
of 100 nucleotides (i.e. ﬁrst window from position 1 to 1000,
second window from 101 to 1100, and so on). The null model was
generated using 1000 randomly shufﬂed versions of each genome.
The number of occurrences of the motif (TC, TTC, etc.) in each
randomly shufﬂed sequence was used to build a null model
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distribution for that window. If the true frequency that was
observed in the unshufﬂed sequence was within the lowest 5th
percentile of this distribution, we labeled that window as being
underrepresented. Conversely, if the true frequency was in the
highest 5th percentile, the window was labeled as overrepre-
sented for that motif. The NCBI accession numbers for the
genomes analyzed are: Human papilloma virus type 16
(NC_001526), Herpes simplex virus 1(NC_001806), Herpes simplex
virus 2(NC_001798), Varicella-zoster virus (NC_001348), Epstein-
Barr virus (NC_007605), Human cytomegalovirus (NC_006273),
Human herpesvirus 6A (NC_001664), Human herpesvirus 6B
(NC_000898), Human herpesvirus 7(NC_001716), Kaposi's
sarcoma-associated herpesvirus (NC_009333) and Murine gam-
maherpesvirus 68 (NC_001826).
Statistical analyses
Data was analyzed using Graphpad Prism Software (Prism 5,
La Jolla CA). The statistical signiﬁcance of differences between
groups was tested using a non-paired two-tailed t test. Under
Poisson distribution analysis, the frequencies of latency establish-
ment and reactivation from latency were determined by the
intersection of nonlinear regression curves with the line at 63.2%.
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